Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Asarina Pharma AB (publ) is a biotechnology company focused on developing innovative treatments for central nervous system disorders, particularly in the areas of epilepsy and neurodegenerative diseases. The company operates primarily in Sweden and has a unique competitive advantage through its proprietary drug candidates, which target specific neurological pathways.
Asarina Pharma primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies for the development of its drug candidates. The company has a strong focus on niche therapeutic areas, which allows it to command higher pricing power due to the specialized nature of its products.
Clinical trial results for lead drug candidates
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from health authorities
Market adoption rates of approved therapies
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Emergence of new competitors in the CNS drug market
Potential for larger pharmaceutical companies to develop similar therapies
High operational cash burn due to ongoing R&D expenses
Limited revenue generation leading to liquidity concerns
low - The biotechnology sector is less sensitive to economic cycles as demand for healthcare remains relatively stable regardless of economic conditions.
As a biotech firm, Asarina Pharma is sensitive to interest rates primarily through its cost of capital for funding R&D. Rising rates could increase financing costs, impacting its ability to fund ongoing projects.
minimal - The company has a manageable debt-to-equity ratio of 0.61, indicating limited reliance on credit.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock is likely to exhibit high volatility due to the binary nature of clinical trial outcomes.